- Home
- » Tags
- » Tecovirimat
Top View
- 208627Orig1s000
- FDA ADVISORY COMMITTEE BRIEFING DOCUMENT Tecovirimat for the Treatment of Smallpox Disease Antimicrobial Division Advisory Commi
- Repurposing of FDA Approved Drugs
- Medication Prior Authorization Criteria
- Medicaid List of Covered Drugs (Formulary)
- COVID-19 Reporting Form (PDF)
- WHO Advisory Committee on Variola Virus Research: Report of the Nineteenth Meeting
- Case Report of Laboratory- Acquired Vaccinia Virus Infection in India Cas D'infection En Laboratoire Par Le Virus De La Vaccin
- Miscellaneous Antiviral Agents (Interferons, Tecovirimat, 48 Imiquimod, Pocapavir, Pleconaril) Raphael Dolin and Stephen R
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Appendix a - Product Name Index
- Vaccinia Virus Binding and Infection of Primary Human
- Hep28280 Am.Pdf
- OP01.01 ORAL TECOVIRIMAT for the TREATMENT of SMALLPOX D. W. Grosenbach1,*, K. Honeychurch2, E. Rose3, J. Chinsangaram2, A. Frimm4, B
- (CHMP) Agenda for the Meeting on 09-12 November 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
- Prescription Drug Formulary This Formulary Is for the Community Care Health’S Commercial Large Group and Small Group HMO Business
- Drug Pipeline Monthly Update
- 208627Orig1s000